Citadel Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-126,615
| Closed | -$185K | – | 12624 |
|
|
2025
Q3 | $203K | Buy |
126,615
+71,609
| +130% | +$117K | ﹤0.01% | 11240 |
|
|
2025
Q2 | $77K | Buy |
+55,006
| New | +$82.3K | ﹤0.01% | 11523 |
|
|
2025
Q1 | – | Sell |
-298
| Closed | -$378 | – | 14435 |
|
|
2024
Q4 | $375 | Buy |
298
+275
| +1,196% | +$427 | ﹤0.01% | 14336 |
|
|
2024
Q3 | $43 | Sell |
23
-65,454
| -100% | -$259K | ﹤0.01% | 14105 |
|
|
2024
Q2 | $485K | Sell |
65,477
-42,638
| -39% | -$351K | ﹤0.01% | 8116 |
|
|
2024
Q1 | $847K | Buy |
108,115
+75,707
| +234% | +$487K | ﹤0.01% | 7286 |
|
|
2023
Q4 | $165K | Sell |
32,408
-36,682
| -53% | -$189K | ﹤0.01% | 10242 |
|
|
2023
Q3 | $409K | Sell |
69,090
-102,980
| -60% | -$685K | ﹤0.01% | 8509 |
|
|
2023
Q2 | $1.28M | Buy |
172,070
+103,136
| +150% | +$878K | ﹤0.01% | 5955 |
|
|
2023
Q1 | $651K | Sell |
68,934
-52,488
| -43% | -$554K | ﹤0.01% | 7745 |
|
|
2022
Q4 | $1.29M | Buy |
121,422
+80,314
| +195% | +$815K | ﹤0.01% | 6320 |
|
|
2022
Q3 | $303K | Sell |
41,108
-12,360
| -23% | -$76.8K | ﹤0.01% | 9562 |
|
|
2022
Q2 | $257K | Buy |
53,468
+28,798
| +117% | +$163K | ﹤0.01% | 10157 |
|
|
2022
Q1 | $126K | Buy |
+24,670
| New | +$130K | ﹤0.01% | 12037 |
|
|
2021
Q4 | – | Sell |
-11,001
| Closed | -$82.5K | – | 13761 |
|
|
2021
Q3 | $98K | Buy |
+11,001
| New | +$76.5K | ﹤0.01% | 12897 |
|
|
2021
Q1 | – | Sell |
-46,487
| Closed | -$395K | – | 13136 |
|
|
2020
Q4 | $363K | Buy |
46,487
+30,527
| +191% | +$332K | ﹤0.01% | 8738 |
|
|
2020
Q3 | $155K | Sell |
15,960
-5,472
| -26% | -$60.3K | ﹤0.01% | 8978 |
|
|
2020
Q2 | $226K | Buy |
21,432
+19,138
| +834% | +$145K | ﹤0.01% | 8350 |
|
|
2020
Q1 | $13K | Buy |
+2,294
| New | +$16.3K | ﹤0.01% | 9381 |
|
|
2019
Q4 | – | Sell |
-5,120
| Closed | -$35K | – | 9081 |
|
|
2019
Q3 | $35K | Buy |
+5,120
| New | +$35.6K | ﹤0.01% | 8802 |
|
|
2019
Q1 | – | Sell |
-5,384
| Closed | -$63K | – | 9231 |
|
|
2018
Q4 | $63K | Buy |
+5,384
| New | +$91.8K | ﹤0.01% | 8423 |
|
|
2018
Q3 | – | Sell |
-1,114
| Closed | -$22.7K | – | 9182 |
|
|
2018
Q2 | $21K | Buy |
+1,114
| New | +$14.1K | ﹤0.01% | 8639 |
|
|
2017
Q4 | – | Sell |
-1,952
| Closed | -$34K | – | 7937 |
|
|
2017
Q3 | $34K | Buy |
+1,952
| New | +$42.8K | ﹤0.01% | 7262 |
|
|
2016
Q2 | – | Sell |
-657
| Closed | -$39K | – | 6802 |
|
|
2016
Q1 | $39K | Buy |
657
+354
| +117% | +$22.4K | ﹤0.01% | 6310 |
|
|
2015
Q4 | $29K | Sell |
303
-107
| -26% | -$7.11K | ﹤0.01% | 7682 |
|
|
2015
Q3 | $22K | Sell |
410
-836
| -67% | -$55.8K | ﹤0.01% | 8088 |
|
|
2015
Q2 | $99K | Buy |
+1,246
| New | +$106K | ﹤0.01% | 7084 |
|
Other funds holding ATNM
VCM
GS
VFT
Citadel Advisors's ATNM Position: Q4 2025 in Review
Citadel Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 126,615 shares — an estimated $185K sold.
Citadel Advisors first reported a position in ATNM in Q2 2015 and held it in 27 quarters. The position peaked at $1.29M in Q4 2022. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.
- Citadel Advisors reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 126,615 Actinium Pharmaceuticals shares in Q4 2025, an estimated $185K.
- Citadel Advisors first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 27 quarters.
- Citadel Advisors's Actinium Pharmaceuticals position peaked at $1.29M in Q4 2022.
- 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.